Celltrion, Inc.
068270
Peringkat dalam Saham
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$146.63
Kapitalisasi Pasar
$33.44B
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
23.60%
Negara
KR
Perdagangan Celltrion, Inc. (068270)
Kategori
Healthcare
Riwayat hasil dividen untuk Celltrion, Inc. (068270)
Hasil dividen (TTM) dari Celltrion, Inc. (simbol saham: 068270) per 2024-12-31: 0.26%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.27%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.27%
Riwayat hasil dividen untuk Celltrion, Inc. (068270) dari 2007 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.37% | -5.13% |
| 2025 | 0.39% | 50.00% |
| 2024 | 0.26% | 52.94% |
| 2023 | 0.17% | -66.67% |
| 2022 | 0.51% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | 0.06% | -85.37% |
| 2012 | 0.41% | 86.36% |
| 2011 | 0.22% | -4.35% |
| 2010 | 0.23% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | 5.93% | 220.54% |
| 2007 | 1.85% | 0.00% |
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.07% |
AU
|
|
| 0.56% |
BE
|
|
| 0.00% |
NL
|
